Overview

Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma

Status:
Terminated

Trial end date:
2013-03-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs such as temsirolimus and valproic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Valproic acid may also stop the growth of solid tumors by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and the best dose of temsirolimus when given together with valproic acid in treating young patients with relapsed neuroblastoma, bone sarcoma, or soft tissue sarcoma.

Phase:

Phase 1

Details

Lead Sponsor:

UNC Lineberger Comprehensive Cancer Center

Collaborator:

National Cancer Institute (NCI)

Treatments:

Everolimus
Sirolimus
Valproic Acid